Fecal Microbiota Transplantation as a Cancer Therapeutic

Ronen Stoff1, Yochai Wolf2, Ben Boursi

  • 1From the Ella Lemelbaum institute for immuno-oncology and melanoma, Sheba Medical Center, Ramat Gan.

Insights

The human microbiota, once overlooked, is now recognized as crucial in cancer. This review explores fecal microbiota transplantation as a potential cancer therapy, highlighting the microbiota's role in tumorigenesis and treatment.

Area of Science:

  • Microbiome research and oncology.
  • Cancer as an ecological niche.
  • Microbial modulation in cancer therapy.

Background:

  • Historically, cancer research focused on cellular genetics, neglecting microbiota associations.
  • Early research identified specific microbes as carcinogens (e.g., Helicobacter pylori).
  • Advancements in multiomics confirmed the human body as an 'ecological community'.

Approach:

  • Reviewing the evolving understanding of the microbiota's role in cancer.
  • Focusing on fecal microbiota transplantation (FMT) as a potential therapeutic strategy.
  • Examining the microbiota's influence on tumorigenesis and cancer treatment, particularly immunotherapy.

Key Points:

  • The microbiota plays significant roles in cancer development, treatment efficacy, and toxicity.
  • Fecal microbiota transplantation, a technique for recurrent C. difficile infections, is being investigated for cancer treatment.
  • Understanding cancer as an ecological niche is essential for exploring FMT's therapeutic potential.

Conclusions:

  • The microbiota is an emerging hallmark of cancer.
  • Microbial modulation, including FMT, shows promise in cancer therapy.
  • Further research is needed to elucidate FMT's role in medical oncology.

Related Concept Videos